pharmafile | March 23, 2023 | News story | Business Services  

London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Symbicort (budesonide/formoterol) Turbohaler 200/6 in the United Kingdom as reliever therapy for adults and adolescents (12 years and older) with mild asthma.3 It is already approved in the UK for patients with moderate to severe asthma as Maintenance and Reliever Therapy (MART), and as maintenance therapy only.3


Budesonide/formoterol 200/6 is the first and only dual-combination (ICS/LABA) treatment to be approved in the UK for mild asthma, where a high unmet clinical need exists.1,2 Evidence shows that patients with mild asthma remain at risk of severe asthma attacks, often associated with frequent over-reliance on short-acting beta2-agonist (SABA) inhalers.8 SABAs do not address underlying airway inflammation and for safety reasons are no longer recommended for use as monotherapy.8


This approval is based on positive data from clinical trials in more than 9,500 patients published in The New England Journal of Medicine and The Lancet, and forms a robust body of evidence demonstrating the effectiveness of budesonide/formoterol 200/6 compared with standard of care (SoC) therapies in mild asthma.1,2,4,5


Asthma is a chronic, variable, inflammatory disease characterised by asthma attacks and symptoms including breathlessness and wheezing.9F[10] In the UK it affects an estimated 8 million people.10F[11] Deaths from asthma have increased by more than 26% in the last ten years.11F[12] AstraZeneca estimates that approximately 2.65 million adults in the UK who live with mild asthma could be eligible for this treatment.12F[13]


Professor Ian Pavord, Professor of Respiratory Medicine at the University of Oxford said: “In the UK, asthma attacks remain a major burden in patients diagnosed with mild asthma and these are driven by airway inflammation. Budesonide/formoterol 200/6 reliever therapy helps target airway inflammation and also delivers rapid, long-acting relaxation of the airway. I’m excited by the MHRA’s approval based on data from four key clinical trials which could potentially help address the unmet need for patients living with mild asthma in the UK.”


Ed Piper, Medical & Scientific Affairs Director, AstraZeneca UK, said: “We are delighted that the MHRA is the first regulatory agency in Europe to approve budesonide/formoterol 200/6 for use as a reliever in patients with mild asthma. This approval recognises the clinical utility of budesonide/formoterol 200/6 as an important new treatment option for patients with mild asthma in the UK.”


The safety and tolerability data for budesonide/formoterol 200/6 as needed in mild asthma were consistent with the known profile of the medicine.1,2,4,5


AstraZeneca is committed to improving asthma care for patients in the UK. We are working towards a zero-tolerance approach to asthma attacks in the UK and are committed to reducing asthma-related exacerbations in a sustainable way that benefits both the patient community and the environment alike.



[10] World Health Organisation. Asthma. Available at:,Asthma%20is%20a%20chronic%20disease%20characterized%20by%20recurrent%20attacks%20of,with%20chest%20tightness%20and%20cough. Last accessed: March 2023

[11] British Lung Foundation. Asthma statistics. Available at: Last accessed: March 2023.

[12] Asthma + Lung UK. Transforming asthma care in the UK. Available at: Last accessed: March 2023

[13] AstraZeneca. Data on file. REF-179537.

Related Content

No items found

Latest content